BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21707858)

  • 1. Serum homocysteine and physical exercise in patients with Parkinson's disease.
    Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
    Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
    Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
    Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
    Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
    Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
    Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
    J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
    O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
    Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
    Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
    J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
    Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
    Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD).
    Song IU; Kim JS; Park IS; Kim YD; Cho HJ; Chung SW; Lee KS
    Arch Gerontol Geriatr; 2013; 57(3):288-91. PubMed ID: 23706974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
    Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
    Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
    Kocer B; Guven H; Comoglu SS
    Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
    O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
    Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.